BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31621674)

  • 1. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
    Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
    Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
    Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
    Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P
    Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
    Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
    Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
    Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
    Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
    Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
    Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.
    Rao VK; Lobato RL; Bartlett B; Klanjac M; Mora-Mangano CT; Soran PD; Oakes DA; Hill CC; van der Starre PJ
    J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1221-6. PubMed ID: 25281040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
    Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
    Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
    Končar IB; Davidović LB; Savić N; Sinđelić RB; Ilić N; Dragas M; Markovic M; Kostic D
    J Vasc Surg; 2011 Apr; 53(4):1032-7. PubMed ID: 21215579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
    von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C
    Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA; Russell IA; Williams GD
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study.
    Hoffmann T; Assmann A; Dierksen A; Roussel E; Ullrich S; Lichtenberg A; Albert A; Sixt S
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1564-1573.e8. PubMed ID: 29884487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
    Tomita E; Takase H; Tajima K; Suematsu Y
    Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.
    Baral P; Cotter E; Gao G; He J; Wirtz K; Sharma A; Zorn Iii T; Muehlebach G; Flynn B
    J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2133-2140. PubMed ID: 30772178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of recombinant activated factor VIIa for major bleedings in open heart surgery].
    Ingimarsson JP; Onundarson PT; Valsson F; Vidarsson B; Gudbjartsson T
    Laeknabladid; 2008 Sep; 94(9):607-12. PubMed ID: 18784387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery.
    Sutherland L; Houchin A; Wang T; Wang S; Moitra V; Sharma A; Zorn T; Flynn BC
    J Cardiothorac Vasc Anesth; 2022 Jan; 36(1):147-154. PubMed ID: 34103218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
    Brase J; Finger B; He J; Wirtz K; Stun L; McMillen R; Flynn B
    Ann Thorac Surg; 2016 Jul; 102(1):35-40. PubMed ID: 26874365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
    Raivio P; Suojaranta-Ylinen R; Kuitunen AH
    Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.
    Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.